Labiotech.eu

News and Trends 12 Dec 2017

British Biotech Gets $15M as its Armed Oncolytic Virus Enters the Clinic

PsiOxus will receive a generous milestone payment from Bristol-Myers Squibb, which licenses the biotech’s oncolytic virus technology. PsiOxus hopes to become the world’s leading immuno-oncolytic company, systemically administering “gene therapy for tumors.” Today, the biotech has announced that its Clinical Trial Application for NG-348 for the treatment of solid tumors, has been approved. Under the terms of […]

December 12, 2017 - 2 minutesmins - By Alex Dale

News and Trends 12 Dec 2017

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has deemed Immunocore’s technology worth being used by patients before it’s approved. The regulatory agency has granted Promising Innovative Medicines (PIM) designation to IMCgp100 for […]

December 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2017

New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH

NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a disease with no treatment and a huge market. With a €25M investment in Series A, NorthSea Therapeutics is all set to start Phase II trials in nonalcoholic steatohepatitis (NASH) and take on a very profitable market. The fundraising was led by Forbion […]

December 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2017

An FDA First! Sanofi’s “Follow-on” Insulin Gets a Thumbs Up

Sanofi’s rapid-action insulin, Admelog, will be the first “follow-on” insulin product on the market to help diabetics manage their blood sugar at mealtimes. Sanofi has announced the FDA approval of Admelog, the first “follow-on” mealtime insulin available to type 1 and type 2 diabetics. This gave the company’s stock price a boost of 1.1% this morning, which is […]

December 12, 2017 - 3 minutesmins - By Alex Dale

News and Trends 12 Dec 2017

The Largest Medtech Fund in Europe is Here Thanks to This Dutch VC

LSP has closed a €280M fund, Health Economics Fund 2, that is dedicated to medtech with a focus on containing costs while delivering effective healthcare. There’s a new medtech fund in town, Health Economics Fund 2 (HEF 2), and it’s the largest in Europe. Managed by Partners Anne Portwich, Rudy Dekeyser, Fouad Azzam, Clemens van Blitterswiik, […]

December 12, 2017 - 2 minutesmins - By Evelyn Warner

Best in Biotech 12 Dec 2017

Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017

As 2016 was a tough year for biotech, 2017 was under pressure to turn things around. Although there has been an improvement, there were some notable speed bumps for the industry. 2017 started brightly, with 14 FDA approvals by April – a big improvement on 2016, which only saw 22 in the whole year. The […]

December 12, 2017 - 7 minutesmins - By Alex Dale

News and Trends 11 Dec 2017

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease […]

December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 11 Dec 2017

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech ADC Therapeutics is one of our top biotechs of the year after it brought in a massive $200M (€170M) fundraising round. The company develops antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Results from two Phase I studies […]

December 11, 2017 - 3 minutesmins - By Alex Dale

News and Trends 11 Dec 2017

Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations?

Mereo BioPharma’s drug, BCT-197, more than halved the number of hospitalizations of chronic obstructive pulmonary disease patients during a Phase II trial. Mereo BioPharma develops therapies for patients with rare diseases. Today, it has announced that BCT-197, or acumapimod, improved lung function and reduced the number of hospitalizations for treatment in chronic obstructive pulmonary disease (COPD) patients. One of […]

December 11, 2017 - 3 minutesmins - By Alex Dale

Interview 11 Dec 2017

Edwin Moses on how Ablynx has made it to the top of European biotech

Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […]

December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

wilsons disease treatment wilson therapeutics sweden 1

News and Trends 8 Dec 2017

Wilson’s Disease Treatment Gets a €24.4M Equity Boost in Sweden

Wilson Therapeutics has issued new shares on Nasdaq Stockholm, raising a total of SEK 244M (€24.4M) to help bring its Wilson’s disease treatment to the market. Stockholm-based biotech Wilson Therapeutics has closed a share issue that seems to have generated quite a high demand. The company’s main shareholders, Abingworth and MVM, had to sell SEK 156.75M […]

December 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2017

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.” Based in London, the biotech company TopiVert is trying to enter the $3Bn market of dry eye syndrome with a drug with the potential to work better than the options currently […]

December 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

British Biotech Gets $15M as its Armed Oncolytic Virus Enters the Clinic

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH

An FDA First! Sanofi’s “Follow-on” Insulin Gets a Thumbs Up

The Largest Medtech Fund in Europe is Here Thanks to This Dutch VC

Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations?

Edwin Moses on how Ablynx has made it to the top of European biotech

Wilson’s Disease Treatment Gets a €24.4M Equity Boost in Sweden

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!